检索历史 清除

糖尿病黄斑缺血(DMI)是糖尿病视网膜病变(DR)的表现之一,可与糖尿病黄斑水肿(DME)同时出现,对DR患者的视力造成影响.FFA是诊断DMI的金标准,但随着OCT血管成像的出现,DMI的评估有了更便捷、多样的方法,使得越来越多的研究者开始对DMI进行研究.玻璃体腔注射抗VEGF治疗已成为DME的首选治疗方案,临床医师在进行病例选择时通常排除DMI患者,但DMI作为抗VEGF治疗的禁忌症尚未定论.总结分析DMI的危险因素、评估方法以及抗VEGF对其的治疗结果,可为开展进一步临床研究提供参考,并为制定更合理有效的DME治疗方案提供依据.

Diabetic macular ischemia (DMI) is one of the manifestation of diabetic retinopathy (DR).It could be associated with diabetic macular edema (DME),which may affect the vision of DR patients.FFA is the gold standard for the diagnosis of DMI,but with the advent of OCT angiography,a more convenient and diversified method for the evaluation of DMI has been developed,which makes more and more researchers start to study DMI.Intravitreal injection of anti-VEGF has become the preferred treatment for DME.When treating with DME patients,ophthalmologists usually avoid DMI patients.But if intravitreal anti-VEGF should be the contradiction of DME is still unclear.To provide references to the research,this article summarized the risk factors,assessment methods and influence of DMI.This article also analyzed the existing studies,aiming to offer evidences to a more reasonable and effective treatment decision for DME individual.